Get the Stockscreener App
7.30
0.27%
-0.12
Avalo Therapeutics Inc Stock (AVTX) Forecast
The Avalo Therapeutics Inc (AVTX) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $5.8635, representing a -19.68% decrease from the current price of $7.30. The highest analyst price target is $6.535, and the lowest is $5.1921.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month AVTX Price Target
Average 6.0522
(-17.09% Downside)
Is Avalo Therapeutics Inc (AVTX) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 48.49 | Neutral |
| STOCH(9,6) | 46.60 | Neutral |
| STOCHRSI(14) | 59.14 | Neutral |
| MACD(12,26) | -0.0556 | Buy |
| ADX(14) | 31.47 | Buy |
| William %R | -61.64 | Neutral |
| CCI(14) | 18.14 | Neutral |
Buy: 2
Sell: 0
Neutral: 5
Summary: Neutral
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
7.3298
Sell
|
7.4179
Sell
|
| MA20 |
7.3144
Buy
|
7.423
Sell
|
| MA50 |
7.4578
Sell
|
7.8001
Sell
|
| MA100 |
9.2379
Sell
|
8.5015
Sell
|
| MA200 |
9.9144
Sell
|
8.5541
Sell
|
Buy: 1
Sell: 9
Neutral: 0
Summary: Sell
According to our latest analysis, AVTX could be considered a Strong Sell, with 17 technical analysis indicators signaling 3 Buy signals, 9 signaling Sell signals and 5 Neutral signals. This might not be a good time to consider opening new positions on AVTX, as trading bearish markets can be challenging and may result in losses.
- RSI (Relative Strength Index): The RSI(14) value of 48.49 indicates that AVTX is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 46.6 indicates that AVTX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 59.14 indicates that AVTX is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- ADX (Average Directional Index): The ADX value of The ADX value of 31.47 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of 18.14 indicates that AVTX is not in oversold or overbought territory. It suggests a neutral sentiment in the short term.
Long-term AVTX price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Avalo Therapeutics Inc financial reports and earnings history, Avalo Therapeutics Inc (AVTX) stock could reach $10.77 by 2030, $62.12 by 2040 and $85.19 by 2050. See the projected annual prices until 2050 of the Avalo Therapeutics Inc stock below:
- Avalo Therapeutics Inc (AVTX) is expected to reach an average price of $36.39 in 2035, with a high prediction of $36.09 and a low estimate of $36.41. This indicates an $398.52% rise from the last recorded price of $7.30.
- Avalo Therapeutics Inc (AVTX) stock is projected to chart a bullish course in 2040, with an average price target of $63.03, representing an $763.41% surge from its current level. The forecast ranges from a conservative $61.70 to a sky-high $62.12.
- Our analysts predict Avalo Therapeutics Inc (AVTX) to jump 587.92% by 2045, soaring from $47.78 to an average price of $50.22, potentially reaching $49.82. While $47.78 is the low estimate, the potential upside is significant.
- Avalo Therapeutics Inc (AVTX) stock is expected to climb by 2050, reaching an average of $85.30, a $1,069% jump from its current level. However, a wide range of estimates exists, with high and low targets of $85.19 and $85.32, respectively, highlighting the market's uncertainty.
Avalo Therapeutics Inc Stock (AVTX) Year by Year Forecast
Avalo Therapeutics Inc Stock (AVTX) Price Forecast for 2025
Avalo Therapeutics Inc Stock (AVTX) is expected to reach an average price of $6.0099 in 2025, with a high prediction of $7.563 and a low estimate of $4.4568. This indicates an -17.67% fall from the last recorded price of $7.30.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| April, 2025 | $7.445 | $5.1921 | $6.535 | +1.99% |
| May, 2025 | $6.118 | $6.1947 | $6.6283 | -16.19% |
| June, 2025 | $6.6209 | $6.1244 | $5.9244 | -9.30% |
| July, 2025 | $5.2771 | $5.2871 | $7.0584 | -27.71% |
| August, 2025 | $4.62 | $4.4568 | $4.3236 | -36.71% |
| September, 2025 | $4.573 | $4.998 | $4.7824 | -37.36% |
| October, 2025 | $5.1291 | $4.9994 | $4.8491 | -29.74% |
| November, 2025 | $5.9971 | $5.1156 | $5.8521 | -17.85% |
| December, 2025 | $7.2383 | $6.4753 | $6.8083 | -0.85% |
Avalo Therapeutics Inc Stock (AVTX) Price Forecast for 2026
The predicted value for Avalo Therapeutics Inc (AVTX) in 2026 is set at an average of $4.4665. Estimates vary from a peak of $8.6729 to a trough of $0.26, indicating an -38.82% surge from the present price of $7.30.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $7.8012 | $7.2915 | $7.4012 | +6.87% |
| February, 2026 | $6.5591 | $6.8641 | $7.6477 | -10.15% |
| March, 2026 | $5.9171 | $6.6074 | $6.6439 | -18.94% |
| April, 2026 | $5.2133 | $6.2288 | $6.3068 | -28.59% |
| May, 2026 | $8.6541 | $5.2464 | $8.625 | +18.55% |
| June, 2026 | $8.6642 | $8.6515 | $8.6729 | +18.69% |
| July, 2026 | $8.5639 | $8.5693 | $8.6237 | +17.31% |
| August, 2026 | $8.3876 | $8.3883 | $8.5146 | +14.90% |
| September, 2026 | $8.215 | $8.234 | $8.3119 | +12.53% |
| October, 2026 | $8.0894 | $8.0919 | $8.1788 | +10.81% |
| November, 2026 | $7.9703 | $7.997 | $8.0461 | +9.18% |
| December, 2026 | $3.6365 | $0.26 | $7.9335 | -50.18% |
Avalo Therapeutics Inc Stock (AVTX) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Avalo Therapeutics Inc (AVTX) is $13.58, with a high forecast of $27.05 and a low forecast of $0.0982. This indicates an +85.98% increase from the last price of $7.30.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $3.0195 | $3.3629 | $2.9795 | -58.64% |
| February, 2027 | $3.1324 | $3.2127 | $3.1375 | -57.09% |
| March, 2027 | $9.0314 | $2.8053 | $27.05 | +23.72% |
| April, 2027 | $9.8985 | $3.7682 | $11.49 | +35.60% |
| May, 2027 | $1.3071 | $0.2529 | $9.9152 | -82.10% |
| June, 2027 | $3.1147 | $0.1059 | $4.0747 | -57.33% |
| July, 2027 | $1.0312 | $0.0982 | $3.4282 | -85.87% |
| August, 2027 | $2.4171 | $3.7981 | $2.4906 | -66.89% |
| September, 2027 | $13.30 | $5.4635 | $12.56 | +82.13% |
| October, 2027 | $14.17 | $13.62 | $12.80 | +94.08% |
| November, 2027 | $15.62 | $15.36 | $14.80 | +114.01% |
| December, 2027 | $15.58 | $14.73 | $14.80 | +113.49% |
Avalo Therapeutics Inc Stock (AVTX) Price Forecast for 2028
In 2028, Avalo Therapeutics Inc (AVTX) is projected to reach an average price of $17.00, with a high projection of $19.09 and a low estimate of $14.91. This indicates an +132.87% rise from the last price of $7.30.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $19.15 | $16.25 | $17.84 | +162.33% |
| February, 2028 | $18.50 | $19.23 | $19.09 | +153.48% |
| March, 2028 | $16.46 | $17.11 | $17.28 | +125.45% |
| April, 2028 | $17.64 | $16.38 | $17.40 | +141.69% |
| May, 2028 | $17.02 | $17.13 | $17.64 | +133.09% |
| June, 2028 | $17.37 | $16.95 | $16.78 | +137.97% |
| July, 2028 | $15.91 | $17.11 | $17.74 | +117.91% |
| August, 2028 | $15.04 | $14.91 | $15.60 | +106.03% |
| September, 2028 | $14.85 | $15.27 | $15.11 | +103.37% |
| October, 2028 | $15.21 | $15.20 | $14.97 | +108.38% |
| November, 2028 | $15.94 | $15.13 | $15.79 | +118.34% |
| December, 2028 | $16.72 | $16.38 | $16.36 | +129.04% |
Avalo Therapeutics Inc Stock (AVTX) Price Forecast for 2029
The 2029 price forecast for Avalo Therapeutics Inc Stock (AVTX) is $12.91 on average, with a high prediction of $17.65 and a low estimate of $8.1801. This represents an +76.90% increase from the previous price of $7.30.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $17.41 | $17.01 | $17.01 | +138.53% |
| February, 2029 | $16.02 | $16.33 | $17.22 | +119.50% |
| March, 2029 | $15.23 | $16.03 | $16.00 | +108.69% |
| April, 2029 | $14.32 | $15.48 | $15.51 | +96.17% |
| May, 2029 | $17.64 | $14.34 | $17.65 | +141.65% |
| June, 2029 | $17.50 | $17.50 | $17.55 | +139.77% |
| July, 2029 | $17.28 | $17.29 | $17.43 | +136.77% |
| August, 2029 | $16.90 | $16.90 | $17.21 | +131.45% |
| September, 2029 | $16.62 | $16.63 | $16.78 | +127.71% |
| October, 2029 | $16.27 | $16.27 | $16.53 | +122.83% |
| November, 2029 | $16.00 | $16.03 | $16.19 | +119.19% |
| December, 2029 | $10.05 | $8.1801 | $15.93 | +37.62% |
Avalo Therapeutics Inc Stock (AVTX) Price Forecast for 2030
Avalo Therapeutics Inc Stock (AVTX) is expected to reach an average price of $13.51 in 2030, with a high forecast of $26.69 and a low forecast of $0.3305. This signifies an +85.05% surge from the last price of $7.30.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $10.72 | $11.10 | $10.77 | +46.83% |
| February, 2030 | $10.68 | $10.80 | $10.76 | +46.37% |
| March, 2030 | $6.9393 | $10.21 | $19.65 | -4.94% |
| April, 2030 | $1.4234 | $0.4872 | $7.7328 | -80.50% |
| May, 2030 | $11.54 | $0.3305 | $10.70 | +58.07% |
| June, 2030 | $9.7782 | $12.88 | $11.21 | +33.95% |
| July, 2030 | $13.55 | $10.87 | $12.05 | +85.57% |
| August, 2030 | $14.79 | $16.28 | $14.90 | +102.54% |
| September, 2030 | $26.12 | $17.80 | $24.78 | +257.81% |
| October, 2030 | $26.21 | $25.76 | $24.83 | +258.98% |
| November, 2030 | $27.51 | $27.36 | $26.69 | +276.89% |
| December, 2030 | $24.78 | $26.47 | $26.60 | +239.40% |
0.70%
0.95%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):